PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism

PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism

Immune checkpoint inhibitors (ICIs) induce T-cell activation against cancer cells, and due to their anti-tumor function in multiple cancers, ICIs have been considered an important option for oncotherapy. PD-1/PD-L1 inhibitors are now widely used as ICIs for many types of cancers in clinical practice...

Full description

Bibliographic Details
Main Authors:	Hao Dong, Yihang Qi, Xiangyi Kong, Zhongzhao Wang, Yi Fang, Jing Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-04-01
Series:	Frontiers in Pharmacology
Subjects:	immunotherapy myocarditis epidemiology mechanism PD-1/PD-L1 inhibitors
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.835510/full

Similar Items

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
by: Ke Zhang, et al.
Published: (2022-03-01)

Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II
by: Chuqi Lei, et al.
Published: (2023-02-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
by: Tianrui Yang, et al.
Published: (2021-02-01)

Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer
by: Yihang Qi, et al.
Published: (2022-09-01)

Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis
by: Jue Zhu, et al.
Published: (2021-08-01)

Editorial: Toxicity Mechanism and Clinical Features of PD-1/PD-L1 Inhibitors in Treatment of Cancer, Volume I
by: Xiangyi Kong, et al.
Published: (2022-05-01)

The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy
by: Lu Wen, et al.
Published: (2021-12-01)

Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction
by: Fengling Wang, et al.
Published: (2023-02-01)

Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy
by: Fengling Wang, et al.
Published: (2021-03-01)

Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges
by: Fang Yang, et al.
Published: (2021-12-01)

Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era
by: SHAN Baoen
Published: (2023-09-01)

PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
by: Min Luo, et al.
Published: (2021-10-01)

Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
by: André F. Oliveira, et al.
Published: (2019-05-01)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
by: Zhitao Li, et al.
Published: (2021-11-01)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
by: Yuanyuan Wang, et al.
Published: (2021-05-01)

Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for  Non-small Cell Lung Cancer
by: Sixuan WU, et al.
Published: (2019-07-01)

Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis
by: Surui Liu, et al.
Published: (2022-07-01)

Mechanism and Clinical Application of PD-1/PD-L1 Inhibitors in Immunotherapy
by: Yang Xicheng
Published: (2022-01-01)

Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies
by: Li-ping Zhao, et al.
Published: (2022-06-01)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
by: Qian Li, et al.
Published: (2022-12-01)

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
by: Liping Pei, et al.
Published: (2023-02-01)

Unexpected curative effect of PD-1 inhibitor in gastric cancer with brain metastasis: A case report
by: Qijun Wang, et al.
Published: (2023-02-01)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
by: Long Jia, et al.
Published: (2018-06-01)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
by: Seri Jeong, et al.
Published: (2021-10-01)

Virtual Screening and In Vitro Evaluation of PD-L1 Dimer Stabilizers for Uncoupling PD-1/PD-L1 Interaction from Natural Products
by: Jrhau Lung, et al.
Published: (2020-11-01)

Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
by: Ofek Mussafi, et al.
Published: (2022-08-01)

The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers
by: Omid Kooshkaki, et al.
Published: (2020-07-01)

PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
by: Xiaohui Ren, et al.
Published: (2024-04-01)

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
by: Jia-Wen Cui, et al.
Published: (2024-02-01)

Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
by: Chengliang Sun, et al.
Published: (2022-12-01)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
by: Mengling Wu, et al.
Published: (2022-03-01)

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
by: Peiyi Xie, et al.
Published: (2021-11-01)

Case Report: Acute Myocarditis Due to PD-L1 Inhibitor Durvalumab Monotherapy in a Patient With Lung Squamous Cell Carcinoma
by: Bo Zhou, et al.
Published: (2022-06-01)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
by: Miao Wang, et al.
Published: (2021-12-01)

PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines
by: Mohammed Safi, et al.
Published: (2021-03-01)

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy
by: Hongbo Zhang, et al.
Published: (2021-06-01)

IMMUNE RESISTANCE VIA A PD-1/PD-L1 MECHANISM IN GLIOBLASTOMA
by: V.S. KUSHNIROVA, et al.
Published: (2023-12-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
by: Ruiting Li, et al.
Published: (2021-06-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors
by: GAN Zi-ying, TANG Hui
Published: (2022-04-01)